Zentalis Pharmaceuticals Llc (ZNTL) Stock Analysis

Zentalis Pharmaceuticals Llc (ZNTL) is a publicly traded company in the HEALTHCARE sector. It trades at $3.95, carries a market capitalization of $283.32M. This page summarizes the public market data, fundamentals, and frequently asked questions for ZNTL, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Zentalis Pharmaceuticals Llc currently has a Bullish sentiment score of 0.21.

About Zentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, focused on developing innovative small molecule therapies for cancer treatment through precision medicine. The company is advancing a promising pipeline that targets critical pathways involved in tumor growth and resistance, addressing significant unmet medical needs in oncology. Zentalis's strategic approach and commitment to innovation position it as a potential leader in the biopharmaceu...

GNG Research Analysis

GNG Research scores Zentalis Pharmaceuticals Llc (ZNTL) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ZNTL.

Frequently Asked Questions

Does ZNTL pay dividends?

Zentalis Pharmaceuticals Llc (ZNTL) does not currently pay a regular dividend.

What is ZNTL's market cap?

Zentalis Pharmaceuticals Llc (ZNTL) has a market capitalization of $283.32M with a current stock price of $3.95.